Format

Send to

Choose Destination
Rev Alerg Mex. 2019 Oct-Dec;66(4):409-425. doi: 10.29262/ram.v66i4.643.

[Executive Summary of ARIA 2019: Integrated care pathways for allergic rhinitis in Argentina, Spain and Mexico].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Universidad del Salvador, Facultad de Medicina, Buenos Aires, Argentina. ivancev@gmail.com.

Abstract

in English, Spanish

The health and economic impact of allergic diseases are increasing rapidly, and changes in management strategies are required. Its influence reduces the capacity of work and school performance by at least a third. The ICPs of the airways (integrated care pathways for respiratory diseases) are structured multidisciplinary healthcare plans, promoting the recommendations of the guidelines in local protocols and their application to clinical practice. This document presents an executive summary for Argentina, Mexico, and Spain. Next-generation ARIA guidelines are being developed for the pharmacological treatment of allergic rhinitis (AR), using the GRADE-based guidelines for AR, tested with real-life evidence provided by mobile technology with visual analogue scales. It is concluded that in the AR treatment, H1-antihistamines are less effective than intranasal corticosteroids (INCS), in severe AR the INCS represent the first line of treatment, and intranasal combination INCS + anti-H1 is more effective than monotherapy. However, according to the MASK real-life observational study, patients have poor adherence to treatment and often self-medicate, according to their needs.

KEYWORDS:

ARIA; Adherence; Allergic rhinitis; Integrated care pathways; Real life; Self medication

PMID:
32105425
DOI:
10.29262/ram.v66i4.643

Supplemental Content

Loading ...
Support Center